CIGB-300

10/01/2011 - "In the clinical ground, CIGB-300 has proved to be safe and well tolerated in a First-in-Human trial in women with cervical malignancies who also experienced signs of clinical benefit. "
05/13/2009 - "Based on the perspectives of CIGB-300 to treat cancer, this "first-in-human" study investigated its safety and tolerability in patients with cervical malignancies. "
09/01/2008 - "Finally, we performed a First-in-Man trial with CIGB 300 in patients with cervical malignancies. "
07/01/2021 - "Unlike solid tumor cells, NPM1 did not appear to be a major target for CIGB-300 in AML cells. "
06/01/2018 - "CIGB-300 inhibits the CK2-mediated phosphorylation leading to apoptosis of tumor cells in vitro, and in vivo in cancer patients. "

01/01/2020 - "The present preclinical study establishes for the first time the efficacy of CIGB-300 on breast cancer. "
01/01/2020 - "Systemic CIGB-300 treatment inhibited breast cancer colonization of the lung, reducing the size and number of metastatic lesions. "
01/01/2020 - "We demonstrated that CIGB-300 reduces breast cancer cell growth in MDA-MB-231, MCF-7 and F3II cells, exerting a pro-apoptotic action and cell cycle arrest. "
01/01/2020 - "Our aim was to evaluate the potential therapeutic benefits of CIGB-300 on breast cancer disease using experimental models with translational relevance. "
01/01/2020 - "Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization."

01/01/2017 - "We demonstrate that treatment with low micromolar concentrations of CIGB-300 caused a drastic reduction of adhesion, migration and invasion of lung cancer cells. "
06/01/2015 - "In this work, we sought to identify the biological processes modulated by CIGB-300 in a lung cancer cell line using subtractive suppression hybridization and subsequent functional annotation clustering. "
01/01/2017 - "Altogether our data suggest an important role of CK2 in lung tumor development, suggesting a potential use of CIGB-300 as a novel therapeutic agent against lung cancer."
04/01/2012 - "Interestingly, we had previously demonstrated that the putative oncogene B23/nucleophosmin (NPM) is the major intracellular target for CIGB-300 in a sensitive human lung cancer cell line. "
01/01/2017 - "CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models."

05/12/2015 - "We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the recommended dose. "
01/01/2022 - "These findings unveil novel molecular clues to the means by which CIGB-300 triggers cell death in cervical cancer cells."
01/01/2022 - "However, the targeting of E7 phosphorylation by CIGB-300 seemed to be dispensable for the induction of cell death in HPV-18 cervical cancer-derived C4-1 cells. "
05/12/2015 - "Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer."
01/01/2018 - "We also summarize early clinical research (phase 1/2 trials) of CIGB-300 in cervical cancer, including data in combination with chemoradiotherapy. "

12/20/2021 - "Sequence analyses and data from phosphorylation studies were combined to predict infection-induced molecular mechanisms that can be interfered by CIGB-300. "